Literature DB >> 10825709

Influence of GAA expansion size and disease duration on central nervous system impairment in Friedreich's ataxia: contribution to the understanding of the pathophysiology of the disease.

L Santoro1, A Perretti, B Lanzillo, G Coppola, G De Joanna, F Manganelli, S Cocozza, G De Michele, A Filla, G Caruso.   

Abstract

OBJECTIVE: To verify if GAA expansion size could account for the severity of the central nervous system involvement in Friedreich's ataxia (FA).
METHODS: Retrospective study of 52 FA patients (mean age 26.9+/-12.1 years; mean disease duration 10.6+/-7.6 years) homozygous for GAA expansion. Median nerve somatosensory evoked potentials (SSEPs) were available in 36 FA patients, upper limb motor evoked potentials (MEPs) to transcranial magnetic stimulation in 32, brainstem auditory evoked potentials (BAEPs) in 24, and visual evoked potentials (VEPs) in 34. N20, P100, MEP amplitude, SSEP and MEP central conduction time (CCT and CMCT), P100 latency and I-III and I-V interpeak latency, and a BAEP abnormality score were correlated with disease duration and GAA expansion size on the shorter (GAA1) and larger (GAA2) allele in each pair.
RESULTS: The GAA1 size inversely correlated with the N20 amplitude (r = -0.49; P<0. 01). Disease duration directly correlated with CMCT (r = 0.57; P<0.01) and BAEP score (r = 0.61; P<0.01) and inversely with MEP (r = -0.40; P<0.05) and P100 amplitude (r = -0.39; P<0.05).
CONCLUSIONS: Our data suggest that central somatosensory pathway involvement in FA is mainly determined by GAA1 expansion size. Vice versa, degeneration of pyramidal tracts, auditory and visual pathways seems to be a continuing process during the life of FA patients.

Entities:  

Mesh:

Year:  2000        PMID: 10825709     DOI: 10.1016/s1388-2457(00)00290-x

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  9 in total

1.  Generation of induced pluripotent stem cell lines from Friedreich ataxia patients.

Authors:  Jun Liu; Paul J Verma; Marguerite V Evans-Galea; Martin B Delatycki; Anna Michalska; Jessie Leung; Duncan Crombie; Joseph P Sarsero; Robert Williamson; Mirella Dottori; Alice Pébay
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

2.  Frataxin Restoration in the Nervous System: Possibilities for Gene Therapy.

Authors:  David R Lynch; Elizabeth Kichula; Hong Lin
Journal:  Mol Ther       Date:  2018-06-30       Impact factor: 11.454

Review 3.  Friedreich ataxia: clinical features and new developments.

Authors:  Medina Keita; Kellie McIntyre; Layne N Rodden; Kim Schadt; David R Lynch
Journal:  Neurodegener Dis Manag       Date:  2022-06-29

Review 4.  Friedreich ataxia: the clinical picture.

Authors:  Massimo Pandolfo
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 5.  Diagnosis and treatment of Friedreich ataxia: a European perspective.

Authors:  Jörg B Schulz; Sylvia Boesch; Katrin Bürk; Alexandra Dürr; Paola Giunti; Caterina Mariotti; Francoise Pousset; Ludger Schöls; Pierre Vankan; Massimo Pandolfo
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

Review 6.  Transcranial magnetic stimulation in child neurology: current and future directions.

Authors:  Richard E Frye; Alexander Rotenberg; Molliann Ousley; Alvaro Pascual-Leone
Journal:  J Child Neurol       Date:  2007-12-03       Impact factor: 1.987

7.  Hand Dexterity and Pyramidal Dysfunction in Friedreich Ataxia, A Finger Tapping Study.

Authors:  Gilles Naeije; Antonin Rovai; Massimo Pandolfo; Xavier De Tiège
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

8.  Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.

Authors:  Lingli Li; Lucille Voullaire; Chiranjeevi Sandi; Mark A Pook; Panos A Ioannou; Martin B Delatycki; Joseph P Sarsero
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

9.  A Comprehensive Transcriptome Analysis Identifies FXN and BDNF as Novel Targets of miRNAs in Friedreich's Ataxia Patients.

Authors:  Julia O Misiorek; Anna M Schreiber; Martyna O Urbanek-Trzeciak; Magdalena Jazurek-Ciesiołka; Lauren A Hauser; David R Lynch; Jill S Napierala; Marek Napierala
Journal:  Mol Neurobiol       Date:  2020-04-14       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.